Interferon therapy in chronic hepatitis

V. Carreno, J. Bartolome, and I. Castillo, Long-term effect of interferon therapy in chronic hepatitis B, J. Hepatol. 20 431-435 (1994). [Pg.236]

Myers, R.R, Ttubault, V., Poynard, T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J. Viral Hepat. 2003 10 103-110... [Pg.714]

Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987 2(8550) 66-9. [Pg.1842]

Benelhadj S, Marcellin R Castelnau C, et al. Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. Horm Res 1997 48 209-214. [Pg.1388]

Shindo, M., A.M. Di Bisceglie, L. Cheung, et al.. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med,1991.115 700-4. [Pg.184]

Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002 56(6) 793-8. [Pg.672]

Kumar AS, Russo MW, Esposito S, Borezuk A, Jacobson I, Brown M, Brown RS. Severe pulmonary toxicity of interferon and ribavirin therapy in chronic hepatitis C. Am J Gastroenterol 2001 96(Suppl) 127. [Pg.1819]

Ogundipe O, Smith M. Bell s palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrhagic disorders. Haemophilia 2000 6(2) 110-12. [Pg.1820]

Pastore G. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993 13(3) 146-50. [Pg.1828]

Noguchi K, Enjoji M, Nakamuta M, Sugimoto R, Kotoh K, Nawata H. Various sarcoid lesions in a patient induced by interferon therapy for chronic hepatitis C. J Clin Gastroenterol 2002 35(3) 282-4. [Pg.1829]

Soriano V, Bravo R, Samaniego JG, Gonzalez J, Odriozola PM, Arroyo E, Vicario JL, Castro A, Cohnenero M, CarbaUo E, et al. CD4-I- T-lymphocyto-penia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. HIV-Hepatitis Spanish Study Group. AIDS 1994 8(ll) 1621-2. [Pg.1829]

Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyake S, Sakai T, Akiba T, Marumo F, Sato C. Interferon therapy for chronic hepatitis C in hemodialysis patients increased serum levels of interferon. Nephron 1998 80(l) 51-6. [Pg.1830]

Nordmann R, Ribiere C, Rouach H (1992) Implication of free radical mechanisms in ethanol-induced cellular injury. Free Radical Biol Med 112 219-240 Oh KW, Qian T, Brenner DA, Lemasters JJ (2003) Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci 73 44—52 Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K (1996) Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25 283-291 Oleinick NL, Corcoran JW (1969) Two types of binding of erythromycin to ribosomes Ifom antibiotic-sensitive and resistant Saci/te suhtilis 168. J Biol Chem 244 727-735 Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Diff 11 381-389... [Pg.360]

Balan V Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfleld RR, Davis GL, Neumann AU, Osborn BE, Ereimuth WW, Subramanian GM (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy, Antivir Ther 11 35 5... [Pg.230]

Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YE (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 45-52... [Pg.236]

Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7 428 34 Wong DK, Cheung AM, O Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119 312-323... [Pg.242]

B. Indications and nse Infergen is indicated for treating chronic hepatitis C virus (HCV) infection in adults with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA. It is also effective in the subsequent treatment of patients who did not respond or relapsed after initial interferon therapy. In some patients with chronic HCV infection, Infergen normalizes serum alanine aminotransferase (ALT) concentrations, reduces serum HCV RNA concentrations to undetectable quantities (<100 copies/ml), and improves liver histology. [Pg.188]

F. Role in therapy According to Micromedex, Roferon-A is recommended as the drug of choice in renal carcinoma and the chronic phase of chronic myelogenous leukemia. The role of Gleevec (Ima-tinib) in CML is yet to be determined, but it may replace the use of interferon alfa-2a. Roferon-A is an alternative (for unrespon-sive/intolerant patients) to current regimens of choice in hairy-cell leukemia, multiple myeloma, metastatic melanoma, and AIDS-related Kaposi s sarcoma. Other alpha interferons appear to have similar efficacy and can be used in lieu of Roferon-A in some instances. In particular, interferon alfa-2b (Intron) can be considered to have the same role as interferon alfa-2a in chronic hepatitis C, Kaposi s sarcoma, and hairy-cell leukemia. [Pg.191]

Sauleda, S., Juarez, A., Esteban, J. I., Altisent, C., Ruiz, I., Puig, L., Esteban, R., Guardia, J. 2001. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology, 34(5), 1035-1040. [Pg.351]

Neurocognitive performance has been studied in 70 patients receiving interferon alfa 2b (pegylated or conventional) and ribavirin, because impairment of concentration is common during antiviral therapy of chronic hepatitis C (328). Repeated computer-based testing showed significantly increased reaction times. Accuracy... [Pg.671]

In chronic hepatitis B, 5-10% of cases display ANA and/or SMA. Due to the subtle differentiation achieved with HBV markers, it is possible to classify each individual case reliably. Prognosis and therapy are determined by chronic hepatitis B. Interferon therapy can trigger or exacerbate autoimmune hepatitis. (13, 66, 74, 78)... [Pg.681]

Ruiz-Mureno, M., Rua, M.J., Carreno, V, Quironga, J.A., Manns, M., Meyer zum Biischenfelde, K.-H. Autoimmune chronic active hepatitis type 2 manifested during interferon therapy in children. J. Hepatol. 1991 12 265 - 266... [Pg.688]

Bajaj, J.S., Molina, E., Regev, A., Schiff, E.R., Jeffers, L.J. Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2b and ribavirin in chronic hepatitis C. Gastrointest. Endosc. 2003 58 380- 383... [Pg.713]

Di Bisceglie, A.M., Bonkovsky, H.L., Chopra, S., Flamm, S., Reddy, R.K., Grace, N., Killenberg, P., Hunt, C., Tamburro, C., Tavill, A.S., Ferguson, R., Krawitt, E., Banner, B., Bacon, B.R. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon a multicenter, prospective, randomized, controlled trial. Hepatology 2000 32 135-138... [Pg.713]

Thnlnvath, P.J., Pande, H., Maygers, J. Combination therapy with interferon-alpha (2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig. Dis. Sci. 2003 48 594- 597... [Pg.714]

R Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin. Eur. J. Med. Res. 2002 7 149-154... [Pg.714]

Tambini R, Quattrini A, Fracassetti O, Nemni R. Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C. J Rheumatol 1997 24(8) 1656-7. [Pg.1820]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...